Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.

Cancer science - 1 Oct 2005

Yamada Yasuhide, Yamamoto Noboru, Shimoyama Tatsu, Horiike Atsushi, Fujisaka Yasuhito, Takayama Kyoko, Sakamoto Terumi, Nishioka Yuki, Yasuda Sanae, Tamura Tomohide

Abstract excerpt

E7070 is a novel sulfonamide anticancer agent that disrupts the G1/S phase of the cell cycle. The objectives of this phase I study of E7070 were to estimate the maximal tolerated dose (MTD), to determine the recommended dose for phase II, and to clarify the pharmacokinetic profile of E7070 and its relation to polymorphisms of CYP2C9 (*2, *3) and CYP2C19 (*2, *3) in Japanese patients. Patients received 1-2-h i.v....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Drug Administration Schedule

Share to Infusions, Intravenous

Share to Maximum Tolerated Dose

Share to Mixed Function Oxygenases

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 16232205
DOI: 10.1111/j.1349-7006.2005.00109.x
PMCID: PMC11159433

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.PMID 16232205Read ↗

The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology.Semantic proximity Read ↗

Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.Semantic proximity Read ↗

Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.Semantic proximity Read ↗

In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202Semantic proximity Read ↗

Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.Semantic proximity Read ↗

First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors.Semantic proximity Read ↗

Genetic polymorphisms are associated with imatinib plasma levels and periorbital edema in Chinese patients with gastrointestinal stromal tumors receiving adjuvant imatinibSemantic proximity Read ↗

Haplotypes and a novel defective allele of CES2 found in a Japanese population.Semantic proximity Read ↗

Influence of pharmacokinetics-related polymorphisms on asciminib exposure in patients with Japanese chronic myeloid leukemia.Semantic proximity Read ↗

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.Semantic proximity Read ↗

Genome-wide association study of epirubicin-induced leukopenia in Japanese patients.Semantic proximity Read ↗

A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.